A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study to Evaluate the Clinical Efficacy and Safety of OHB-607 Compared to Standard Neonatal Care for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease of Prematurity
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Mecasermin rinfabate (Primary)
- Indications Bronchopulmonary dysplasia; Lung disorders
- Focus Therapeutic Use
- Sponsors Oak Hill Bio; Premacure; Shire; Takeda
- 25 Jul 2024 This trial has been discontinued in Sweden.
- 17 May 2024 According to a Oak Hill Bio media release, the first patient has been enrolled in a resumed Phase 2b clinical study to assess the efficacy and safety of OHB-607.
- 13 May 2024 Planned End Date changed from 28 Nov 2026 to 21 Jan 2028.